27.34
-0.4207(-1.52%)
Currency In USD
Address
40 Erie Street
Cambridge, MA 02139
United States of America
Phone
857 285 6200
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
403
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Dr. Laura Sepp-Lorenzino Ph.D. | Special Advisor to the Chief Executive Officer | 732,682 | 1965 |
| Dr. John M. Leonard M.D. | President, Chief Executive Officer & Director | 1.14M | 1957 |
| Mr. Michael P. Dube | Vice President, CAO & Principal Accounting Officer | 478,489 | 1978 |
| Mr. Edward J. Dulac III | Executive Vice President, Chief Financial Officer and Treasurer | 555,687 | 1976 |
| Mr. James E. Basta Esq., J.D. | Executive Vice President, General Counsel & Corporate Secretary | 656,282 | 1966 |
| Dr. David Lebwohl M.D. | Executive Vice President & Chief Medical Officer | 732,649 | 1955 |
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder | 0 | 1986 |
| Dr. Andrew May Ph.D. | Founder and Member of Scientific Advisor Board | 0 | N/A |
| Dr. Jennifer A. Doudna Ph.D. | Founder & Member of Scientific Advisor Board | 0 | 1964 |
| Dr. Derrick J. Rossi Ph.D. | Founder & Member of Scientific Advisor Board | 0 | N/A |
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.